Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model
暂无分享,去创建一个
[1] G. Schwartz,et al. Treatment implications of the emerging molecular classification system for melanoma. , 2011, The Lancet. Oncology.
[2] H. Putter,et al. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. , 2011, Journal of the American Academy of Dermatology.
[3] K. Flaherty,et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Zavadil,et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. , 2011, Cancer cell.
[5] C. Antonescu,et al. KIT as a therapeutic target in metastatic melanoma. , 2011, JAMA.
[6] S. Ariyan,et al. MicroRNA signatures differentiate melanoma subtypes , 2011, Cell cycle.
[7] L. Poliseno,et al. Distinguishing between nodular and superficial spreading melanoma using specific microRNA alterations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Choi,et al. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.
[9] R. Scolyer,et al. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care , 2011, Molecular oncology.
[10] Jiri Zavadil,et al. Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. , 2011, Cancer research.
[11] Ali Nahvi,et al. A Parsimonious Model for Gene Regulation by miRNAs , 2011, Science.
[12] Mustafa Sahin,et al. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. , 2010, Cell stem cell.
[13] D. Schadendorf,et al. Genetic and morphologic features for melanoma classification , 2010, Pigment cell & melanoma research.
[14] J. O'Brien,et al. Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.
[15] S. Dacic,et al. miRNA expression profiling of lung adenocarcinomas: correlation with mutational status , 2010, Modern Pathology.
[16] Kenneth S Kosik,et al. MicroRNAs and Cellular Phenotypy , 2010, Cell.
[17] F. Hodi,et al. Advances in targeted therapy for melanoma. , 2010, Clinical advances in hematology & oncology : H&O.
[18] M. Zappa,et al. The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past , 2010, Melanoma research.
[19] K. Katsuoka,et al. Nestin is expressed in HMB‐45 negative melanoma cells in dermal parts of nodular melanoma , 2010, The Journal of dermatology.
[20] L. Chin,et al. Integrative Genome Comparison of Primary and Metastatic Melanomas , 2010, PloS one.
[21] Y. Pekarsky,et al. Reprogramming of miRNA networks in cancer and leukemia. , 2010, Genome research.
[22] T. Venesio,et al. Altered molecular pathways in melanocytic lesions , 2010, International journal of cancer.
[23] M. Weinstock,et al. Melanoma thickness trends in the United States, 1988-2006. , 2010, The Journal of investigative dermatology.
[24] Yingdong Zhao,et al. MicroRNA Expression Differentiates Histology and Predicts Survival of Lung Cancer , 2010, Clinical Cancer Research.
[25] D. Jukic,et al. Microrna profiling analysis of differences between the melanoma of young adults and older adults , 2010, Journal of Translational Medicine.
[26] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] N. Tanna,et al. Comparative genomic hybridization for the diagnosis of melanoma , 2009, European Journal of Plastic Surgery.
[28] J. Reis-Filho,et al. Histological and molecular types of breast cancer: is there a unifying taxonomy? , 2009, Nature Reviews Clinical Oncology.
[29] Myles G Cockburn,et al. Increasing burden of melanoma in the United States. , 2009, The Journal of investigative dermatology.
[30] D. Silvers,et al. GAB2 Amplifications Refine Molecular Classification of Melanoma , 2009, Clinical Cancer Research.
[31] Emmanuel Barillot,et al. Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. , 2009, Investigative ophthalmology & visual science.
[32] S. Swetter,et al. Factors related to the presentation of thin and thick nodular melanoma from a population‐based cancer registry in Queensland Australia , 2009, Cancer.
[33] Michael Schmidt,et al. Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype , 2009, Melanoma research.
[34] C. Burge,et al. Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.
[35] Claus Garbe,et al. Melanoma epidemiology and trends. , 2009, Clinics in dermatology.
[36] M. Mazumdar,et al. Changes in the presentation of nodular and superficial spreading melanomas over 35 years , 2008, Cancer.
[37] M. Mazumdar,et al. Shedding of Distinct Cryptic Collagen Epitope (HU177) in Sera of Melanoma Patients , 2008, Clinical Cancer Research.
[38] A. Reeder,et al. The incidence and thickness of cutaneous malignant melanoma in New Zealand 1994-2004. , 2008, The New Zealand medical journal.
[39] K. Flaherty,et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. , 2008, Cancer research.
[40] W. Gerald,et al. Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.
[41] Jane Fridlyand,et al. Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.
[42] E. Herrera‐Ceballos,et al. Thick melanoma: the problem continues , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.
[43] A. de Klein,et al. Molecular cytogenetic analysis of archival uveal melanoma with known clinical outcome. , 2008, Cancer genetics and cytogenetics.
[44] Valerie Speirs,et al. A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer , 2008, Breast Cancer Research and Treatment.
[45] D. Polsky,et al. BAY 43-9006 (sorafenib-BAY) alters proliferation pathways and mutant specific-PCR (MS-PCR) improves detection of BRAF mutations in metastatic melanoma (MM) , 2007 .
[46] S. Formenti,et al. Disruption of Endothelial Cell Interactions with the Novel HU177 Cryptic Collagen Epitope Inhibits Angiogenesis , 2007, Clinical Cancer Research.
[47] R. Millikan,et al. Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma , 2007, Cancer Epidemiology Biomarkers & Prevention.
[48] R. Spang,et al. Gene Expression Signatures for Tumor Progression, Tumor Subtype, and Tumor Thickness in Laser-Microdissected Melanoma Tissues , 2007, Clinical Cancer Research.
[49] M. Trivett,et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.
[50] L. Chin,et al. Growth factors and oncogenes as targets in melanoma: lost in translation? , 2007, Advances in dermatology.
[51] Shuping Zhao,et al. Increased expression of stem cell markers in malignant melanoma , 2007, Modern Pathology.
[52] J. Lundeberg,et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing , 2006, Melanoma research.
[53] Jason S. White,et al. Correlation of comparative genomic hybridization results of 100 archival uveal melanomas with patient survival. , 2006, Cancer genetics and cytogenetics.
[54] G. Saldanha,et al. Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies , 2006, Clinical Cancer Research.
[55] M. Meyerson,et al. Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[56] M. Atkins,et al. Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma , 2006, Cancer.
[57] M. Demierre. Epidemiology and prevention of cutaneous melanoma , 2006, Current treatment options in oncology.
[58] S. Formenti,et al. Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen. , 2006, The American journal of pathology.
[59] M. Ladanyi,et al. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib , 2006, Clinical Cancer Research.
[60] B. Bastian,et al. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool , 2006, Dermatologic therapy.
[61] J. A. Burch,et al. Melanoma, a tumor based on a mutant stem cell? , 2006, The Journal of investigative dermatology.
[62] J. Fridlyand,et al. Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.
[63] H. Yee,et al. Temporal exposure of cryptic collagen epitopes within ischemic muscle during hindlimb reperfusion. , 2005, The American journal of pathology.
[64] R. Houlston,et al. Microarray comparative genomic hybridisation analysis of intraocular uveal melanomas identifies distinctive imbalances associated with loss of chromosome 3 , 2005, British Journal of Cancer.
[65] R. MacKie,et al. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. , 2005, The Journal of investigative dermatology.
[66] A. Kopf,et al. ABCDE--an evolving concept in the early detection of melanoma. , 2005, Archives of dermatology.
[67] Donald R. Miller,et al. Early detection of thick melanomas in the United States: beware of the nodular subtype. , 2005, Archives of dermatology.
[68] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] J. Castle,et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs , 2005, Nature.
[70] Kazuhiro Takahashi,et al. BRAF point mutations in primary melanoma show different prevalences by subtype. , 2004, The Journal of investigative dermatology.
[71] G. Reifenberger,et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas , 2004, International journal of cancer.
[72] M. Frazier,et al. Phase II trial of imatinib mesylate (STI-571) in metastatic melanoma (MM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[73] Ajay N. Jain,et al. Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.
[74] L. Kanter,et al. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[75] A. Pardee,et al. Analysing differential gene expression in cancer , 2003, Nature Reviews Cancer.
[76] B. Mcavoy,et al. Nodular melanoma. No longer as simple as ABC. , 2003, Australian family physician.
[77] Lin Fritschi,et al. Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection. , 2003, Journal of the American Academy of Dermatology.
[78] P. Carli,et al. Unexpected reduction of mortality rates from melanoma in males living in central Italy. , 2003, European journal of cancer.
[79] P. Meltzer,et al. High frequency of BRAF mutations in nevi , 2003, Nature Genetics.
[80] N. Hayward,et al. Loss of p16 expression is associated with histological features of melanoma invasion , 2002, Melanoma research.
[81] Richard Wooster,et al. BRAF and RAS mutations in human lung cancer and melanoma. , 2002, Cancer research.
[82] P. Meltzer,et al. A genome-based strategy uncovers frequent BRAF mutations in melanoma. , 2002, Cancer cell.
[83] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[84] T. Golub,et al. DNA microarrays in clinical oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[86] Jingsong Xu,et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo , 2001, The Journal of cell biology.
[87] R. Ádány,et al. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. , 2001, Cytometry.
[88] Emanuel Petricoin,et al. Molecular profiling of human cancer , 2000, Nature Reviews Genetics.
[89] D. Lipsker,et al. Striking increase of thin melanomas contrasts with stable incidence of thick melanomas. , 1999, Archives of dermatology.
[90] J. Radhi. Malignant Melanoma Arising from Nevi, p53, p16, and Bcl-2: Expression in Benign versus Malignant Components , 1999, Journal of cutaneous medicine and surgery.
[91] D. Wong,et al. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma , 1998, Journal of cutaneous pathology.
[92] Y. Collan,et al. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage , 1997, International journal of cancer.
[93] T. Saida,et al. Immunohistochemical detection of CDK4 and 9 16INK4 proteins in cutaneous malignant melanoma , 1996, The British journal of dermatology.
[94] F. Haluska,et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. , 1995, Cancer research.
[95] G. Burg,et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma. , 1995, Journal of cancer research and clinical oncology.
[96] S. van der Flier,et al. Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis. , 1995, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[97] J. Hoeffler,et al. Ras mutations in human melanoma: a marker of malignant progression. , 1994, The Journal of investigative dermatology.
[98] M. Mihm,et al. The histopathology of cutaneous malignant melanoma. , 1993, Seminars in diagnostic pathology.
[99] L. J. Veer,et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites , 1989, Molecular and cellular biology.
[100] C. Cordon-Cardo,et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. , 1989, Oncogene.
[101] L. Old,et al. Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? , 1984, Nature.
[102] A. Ackerman. Malignant melanoma: a unifying concept. , 1980, Human pathology.
[103] Ackerman Ab. Malignant melanoma. A unifying concept. , 1980 .
[104] W. Clark,et al. The classification of malignant melanoma and its histologic reporting , 1973, Cancer.
[105] W. Clark,et al. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. , 1969, Cancer research.
[106] MOLES AND MALIGNANT MELANOMA: TERMINOLOGY AND CLASSIFICATION , 1967, The Medical journal of Australia.